Cargando…

Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

Pharmaceutical expenditures in ambulatory care rose rapidly in Europe in the 1990s and early 2000s. This was typically faster than other components of healthcare spending, leading to reforms to moderate future growth. A number of these centered on generic medicines with measures to lower reimbursed...

Descripción completa

Detalles Bibliográficos
Autores principales: Godman, Brian, Shrank, William, Wettermark, Bjorn, Andersen, Morten, Bishop, Iain, Burkhardt, Thomas, Garuolienè, Kristina, Kalaba, Marija, Laius, Ott, Joppi, Roberta, Sermet, Catherine, Schwabe, Ulrich, Teixeira, Inês, Tulunay, F. Cankat, Wendykowska, Kamila, Zara, Corinne, Gustafsson, Lars L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033935/
https://www.ncbi.nlm.nih.gov/pubmed/27713363
http://dx.doi.org/10.3390/ph3082470
_version_ 1782317899579392000
author Godman, Brian
Shrank, William
Wettermark, Bjorn
Andersen, Morten
Bishop, Iain
Burkhardt, Thomas
Garuolienè, Kristina
Kalaba, Marija
Laius, Ott
Joppi, Roberta
Sermet, Catherine
Schwabe, Ulrich
Teixeira, Inês
Tulunay, F. Cankat
Wendykowska, Kamila
Zara, Corinne
Gustafsson, Lars L.
author_facet Godman, Brian
Shrank, William
Wettermark, Bjorn
Andersen, Morten
Bishop, Iain
Burkhardt, Thomas
Garuolienè, Kristina
Kalaba, Marija
Laius, Ott
Joppi, Roberta
Sermet, Catherine
Schwabe, Ulrich
Teixeira, Inês
Tulunay, F. Cankat
Wendykowska, Kamila
Zara, Corinne
Gustafsson, Lars L.
author_sort Godman, Brian
collection PubMed
description Pharmaceutical expenditures in ambulatory care rose rapidly in Europe in the 1990s and early 2000s. This was typically faster than other components of healthcare spending, leading to reforms to moderate future growth. A number of these centered on generic medicines with measures to lower reimbursed prices as well as enhance their prescribing and dispensing. The principal objective of this paper is to review additional measures that some European countries can adopt to further reduce reimbursed prices for generics. Secondly, potential approaches to address concerns with generics when they arise to maximize savings. Measures to enhance the prescribing of generics will also briefly be discussed. A narrative review of the extensive number of publications and associated references from the co-authors was conducted supplemented with known internal or web-based articles. In addition, health authority and health insurance databases, principally from 2001 to 2007, were analyzed to assess the impact of the various measures on price reductions for generic omeprazole and generic simvastatin vs. pre-patent loss prices, as well as overall efficiency in Proton Pump Inhibitor (PPI) and statin prescribing. The various initiatives generally resulted in considerable lowering of the prices of generics as well as specifically for generic omeprazole and generic simvastatin vs. pre-patent loss prices. At one stage in the UK, generic simvastatin was just 2% of the originator price. These measures also led to increased efficiency for PPI and statin prescribing with reimbursed expenditure for the PPIs and statins either falling or increasing at appreciably lower rates than increases in utilization. A number of strategies have also been introduced to address patient and physician concerns with generics to maximize savings. In conclusion, whilst recent reforms have been successful, European countries must continue learning from each other to fund increased volumes and new innovative drugs as resource pressures grow. Policies regarding generics and their subsequent impact on reimbursement and utilization of single sourced products will continue to play a key role to release valuable resources. However, there must continue to be strategies to address concerns with generics when they exist.
format Online
Article
Text
id pubmed-4033935
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-40339352014-05-27 Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe? Godman, Brian Shrank, William Wettermark, Bjorn Andersen, Morten Bishop, Iain Burkhardt, Thomas Garuolienè, Kristina Kalaba, Marija Laius, Ott Joppi, Roberta Sermet, Catherine Schwabe, Ulrich Teixeira, Inês Tulunay, F. Cankat Wendykowska, Kamila Zara, Corinne Gustafsson, Lars L. Pharmaceuticals (Basel) Review Pharmaceutical expenditures in ambulatory care rose rapidly in Europe in the 1990s and early 2000s. This was typically faster than other components of healthcare spending, leading to reforms to moderate future growth. A number of these centered on generic medicines with measures to lower reimbursed prices as well as enhance their prescribing and dispensing. The principal objective of this paper is to review additional measures that some European countries can adopt to further reduce reimbursed prices for generics. Secondly, potential approaches to address concerns with generics when they arise to maximize savings. Measures to enhance the prescribing of generics will also briefly be discussed. A narrative review of the extensive number of publications and associated references from the co-authors was conducted supplemented with known internal or web-based articles. In addition, health authority and health insurance databases, principally from 2001 to 2007, were analyzed to assess the impact of the various measures on price reductions for generic omeprazole and generic simvastatin vs. pre-patent loss prices, as well as overall efficiency in Proton Pump Inhibitor (PPI) and statin prescribing. The various initiatives generally resulted in considerable lowering of the prices of generics as well as specifically for generic omeprazole and generic simvastatin vs. pre-patent loss prices. At one stage in the UK, generic simvastatin was just 2% of the originator price. These measures also led to increased efficiency for PPI and statin prescribing with reimbursed expenditure for the PPIs and statins either falling or increasing at appreciably lower rates than increases in utilization. A number of strategies have also been introduced to address patient and physician concerns with generics to maximize savings. In conclusion, whilst recent reforms have been successful, European countries must continue learning from each other to fund increased volumes and new innovative drugs as resource pressures grow. Policies regarding generics and their subsequent impact on reimbursement and utilization of single sourced products will continue to play a key role to release valuable resources. However, there must continue to be strategies to address concerns with generics when they exist. MDPI 2010-08-05 /pmc/articles/PMC4033935/ /pubmed/27713363 http://dx.doi.org/10.3390/ph3082470 Text en © 2010 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Godman, Brian
Shrank, William
Wettermark, Bjorn
Andersen, Morten
Bishop, Iain
Burkhardt, Thomas
Garuolienè, Kristina
Kalaba, Marija
Laius, Ott
Joppi, Roberta
Sermet, Catherine
Schwabe, Ulrich
Teixeira, Inês
Tulunay, F. Cankat
Wendykowska, Kamila
Zara, Corinne
Gustafsson, Lars L.
Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
title Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
title_full Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
title_fullStr Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
title_full_unstemmed Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
title_short Use of Generics—A Critical Cost Containment Measure for All Healthcare Professionals in Europe?
title_sort use of generics—a critical cost containment measure for all healthcare professionals in europe?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4033935/
https://www.ncbi.nlm.nih.gov/pubmed/27713363
http://dx.doi.org/10.3390/ph3082470
work_keys_str_mv AT godmanbrian useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT shrankwilliam useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT wettermarkbjorn useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT andersenmorten useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT bishopiain useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT burkhardtthomas useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT garuolienekristina useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT kalabamarija useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT laiusott useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT joppiroberta useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT sermetcatherine useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT schwabeulrich useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT teixeiraines useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT tulunayfcankat useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT wendykowskakamila useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT zaracorinne useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope
AT gustafssonlarsl useofgenericsacriticalcostcontainmentmeasureforallhealthcareprofessionalsineurope